Classic psychedelic and cannabis use among U.S. cancer survivors aged ≥ 50 years: nationally representative estimates by cancer type/site.

PurposeTo examine the prevalence of lifetime ("ever") cannabis and classic psychedelic use, and their co-use among U.S. adults aged ≥ 50 years with versus without a lifetime history of cancer, and to describe variation by cancer type/site among survivors.MethodsWe analyzed pooled 2015-2019 and 2021-2022 National Survey on Drug Use and Health (NSDUH) data of U.S. adults aged ≥ 50 years (Unweighted; n = 42,815 for 2015-2019; n = 21,144 for 2021-2022). Lifetime cannabis and classic psychedelic (LSD, psilocybin, peyote/mescaline) use and cancer history (physician-diagnosed, self-reported) were assessed. Weighted prevalence estimates and 95% CIs were computed, and subgroup analyses by cancer type/site were conducted.ResultsBetween 2015 and 2019, cannabis use was similar among cancer survivors (41.6%, 95% CI40.0-43.2) and individuals without cancer (42.6%, 95% CI42.0-43.2, p = 0.21). LSD (8.9, 95% CI8.1-9.7 vs 10.3, 95% CI9.8-10.8) and psilocybin (6.4, 95% CI5.6-7.3 vs 7.7, 95% CI7.4-8.1) were lower among cancer survivors. Any classic psychedelic use was 11.6% (95% CI10.6-12.5) among cancer survivors versus 12.9% (95% CI12.4-13.3) among those without cancer (p